Surgical resection after neoadjuvant concurrent chemoradiotherapy for stage Ⅲ invasive thymic tumor: A phase Ⅱ prospective clinical trial
Chang-lu WANG,Chang-xing L(U),Lan-ting GAO,Jun LIU,Jin-dong GUO,Wen-tao FANG,Jian-xin SHI
DOI: https://doi.org/10.3781/j.issn.1000-7431.2015.33.672
2015-01-01
Tumor
Abstract:Objective: To evaluate the response rate, complete resection rate (R0 resection rate) and survival rate of patients with stage Ⅲ invasive thymic tumor who underwent surgery after neoadjuvant concurrent chemoradiotherapy, and to evaluate the survival rate of the patients with inoperable tumors after inductive chemoradiotherapy and receiving consolidation therapy thereafter.Methods: Patients with pathological biopsy-proved thymic tumors which were classified as invasive stage Ⅲ by radiologic images were recruited in this study. The induction regimen included concurrent radiotherapy and 1-2 cycles of chemotherapy. The radiotherapy was delivered in three dimension conformal radiotherapy or intensity modulated radiotherapy at a dose of 40 Gy/20 fx from day 1. Meanwhile, the chemotherapy consisted of docetaxol (65 mg·m–2·d–1, d 1) and cisplatin (35 mg·m–2·d–1, d1-2), which might be given for a second time on d 28 if judged endurable by patient’s performance status. The tumors were re-evaluated 3-4 weeks after the end of inductive chemoradiotherapy. The operable tumors were removed by surgical resection, while those inoperable ones were irradiated to a definitive dose (total dose of 60 Gy/30 fx). Post-operative adjuvant treatment including radiotherapy and chemotherapy was implemented individually according to the status of residual tumor and the pathologic type.Results: From November 2008 to October 2013, totally 33 eligible patients were included in this study. All patients completed inductive radiotherpy and at least one cycle of concurrent chemotherapy. Among them, 19 patients completed 2 cycles of concurrent chemotherapy. After induction therapy, by radiologic images, 1 patient achieved complete response (CR), 25 patients achieved partial response (PR), while the remaining 7 displayed stable disease (SD). The main adverse effect of induction therapy was neutropenia. Of 26 patients achieving CR+PR, 21 underwent surgical resection, among them, 7 (33%) showed pathologically CR (pCR) after the examination of resected specimen. The 3-year overall survival (OS) rate of 33 patients was 60%. The 3-year OS rates of surgical group and non-surgical group were 50% and 67%, respectively (P = 0.78). For thymoma and thymic carcinoma, the 3-year OS rates were 78% and 52%, respectively (P = 0.58). The failure pattern was mainly demonstrated as distant metastasis, about 43% (9/21) of the thymic carcinoma patients eventually developed distant metastasis.Conclusion: As an induction therapy, concurrent chemoradiotherapy can achieve a high response rate and most of the surgical candidates resulted in complete resection. For high-grade thymic carcinoma, chemoradiotherapy-based non-surgical modalities are recommended as major treatment. Wide-spectrum chemotherapy regimens should be adopted as consolidation treatment for thymic carcinoma. DOI:10.3781/j.issn.1000-7431.2015.33.672